2. Search Result
Search Result
Results for "

Clostridium difficile

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

3

Peptides

2

Inhibitory Antibodies

6

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17580
    Fidaxomicin
    5+ Cited Publications

    OPT-80; PAR-101

    		 DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection
    Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .
    Fidaxomicin
  • HY-B0975A
    Penicillin V

    Phenoxymethylpenicillin

    		 Antibiotic Bacterial Infection
    Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis .
    Penicillin V
  • HY-107830
    Methyl cholate

    		Endogenous Metabolite Collagen Infection Metabolic Disease
    Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis .
    Methyl cholate
  • HY-P9929
    Bezlotoxumab
    1 Publications Verification

    BLA761046; MBL-CDB1; MDX-1388

    		 Bacterial Infection
    Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
    Bezlotoxumab
  • HY-100436
    Cadazolid

    ACT-179811

    		 Bacterial Antibiotic Infection
    Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.
    Cadazolid
  • HY-B1143
    Broxaldine

    Brobenzoxaldine

    		 Parasite Fungal Bacterial Infection
    Broxaldine (Brobenzoxaldine) is an antiprotozoal agent. Broxaldine inhibits Clostridium difficile with a MIC value of 4 µM, and has antifungal effects .
    Broxaldine
  • HY-128357
    Ibezapolstat
    4 Publications Verification

    ACX-362E; GLS-362E

    		 Bacterial DNA/RNA Synthesis Infection
    Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI) .
    Ibezapolstat
  • HY-103249
    Reutericyclin

    Reutericycline

    		 Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-P1108A
    Astressin 2B TFA
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
    Astressin 2B TFA
  • HY-112253
    D-Fructose 1-phosphate

    		Endogenous Metabolite Metabolic Disease
    D-Fructose 1-phosphate is a key intermediate metabolite in the fructose metabolic pathway. As a key signaling molecule linking fructose metabolism and glucose metabolic regulation, D-Fructose 1-phosphate acts as an allosteric modulator to counteract the inhibitory effect of the glucokinase-regulatory protein complex, thereby finely regulating the direction of hepatic glucose metabolism at the substrate level .
    D-Fructose 1-phosphate
  • HY-105099
    Rifalazil

    KRM-1648; ABI-1648

    		 Antibiotic DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .
    Rifalazil
  • HY-18324
    CRS3123
    1 Publications Verification

    REP-3123

    		 Antibiotic Inflammation/Immunology
    CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNA synthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections .
    CRS3123
  • HY-17580S
    Fidaxomicin-d7

    		Isotope-Labeled Compounds DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection
    Fidaxomicin-d7 (OPT-80-D7) is the deuterium labeled Fidaxomicin. Fidaxomicin (OPT-80), a macrocyclic RNA polymerase inhibitor, has a narrow spectrum of activity. Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora .
    Fidaxomicin-d7
  • HY-105017
    Evodenoson

    ATL 313; DE 112

    		 Adenosine Receptor Infection Inflammation/Immunology
    Evodenoson is a selective agonist of the A2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α) .
    Evodenoson
  • HY-P99134
    Anti-Mouse GM-CSF Antibody (MP1-22E9)
    1 Publications Verification

    		 c-Fms Infection Inflammation/Immunology Cancer
    Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis .
    Anti-Mouse GM-CSF Antibody (MP1-22E9)
  • HY-P11114
    Periplanetasin-4

    		Bacterial p38 MAPK Reactive Oxygen Species (ROS) Apoptosis Caspase Infection Inflammation/Immunology
    Periplanetasin-4 is an antimicrobial peptide that can be derived from the American cockroach (Periplaneta americana). Periplanetasin-4 reduces cell rounding and apoptosis. Periplanetasin-4 blocks Clostridium difficile toxin A-induced ROS production and the activation of downstream p38 MAPK and p21. Periplanetasin-4 significantly increases mitochondrial calcium level, reduces DPH fluorescence intensity and vacuolar dysfunction in Candida albicans ATCC 90028 cells. Periplanetasin-4 significantly ameliorates toxin A-induced mucosal damage in the mouse gut. Periplanetasin-4 can be used for the study of colitis .
    Periplanetasin-4
  • HY-P10204
    FZD7 antagonist 1

    		Wnt Cancer
    FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC50 value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .
    FZD7 antagonist 1
  • HY-17580R
    Fidaxomicin (Standard)

    OPT-80 (Standard); PAR-101 (Standard)

    		 Reference Standards DNA/RNA Synthesis Bacterial Apoptosis Antibiotic Infection
    Fidaxomicin (Standard) is the analytical standard of Fidaxomicin. This product is intended for research and analytical applications. Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .
    Fidaxomicin (Standard)
  • HY-159955
    DC-159a

    		Bacterial Infection
    DC-159a is an 8-methoxyfluoroquinolone with broad-spectrum antimicrobial activity, especially against Gram-positive pathogens. DC-159a against Peptostreptococcus, Clostridium difficile, and Bacteroides fragilis with MIC90 values of 0.5, 4, and 2 μg/mL, respectively .
    DC-159a
  • HY-B0975AR
    Penicillin V (Standard)

    Phenoxymethylpenicillin (Standard)

    		 Reference Standards Antibiotic Bacterial Infection
    Penicillin V (Standard) is the analytical standard of Penicillin V. This product is intended for research and analytical applications. Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis [4].
    Penicillin V (Standard)
  • HY-N12228
    Phenelfamycin E

    		Bacterial Antibiotic Infection
    Phenelfamycin E is an elfamycin-type antibiotic and is active against Gram-positive anaerobes, including Clostridium difficile. Phenelfamycin E can be used for anti-bacteria research .
    Phenelfamycin E
  • HY-123354
    SC 44914

    		Bacterial Infection
    SC 44914 is a quinoxaline compound with antibacterial effects. SC-44914 has activity against Campylobacter jejuni, C. coli, and Clostridium difficile .
    SC 44914
  • HY-105099R
    Rifalazil (Standard)

    KRM-1648 (Standard); ABI-1648 (Standard)

    		 Antibiotic Reference Standards DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].
    Rifalazil (Standard)
  • HY-100436R
    Cadazolid (Standard)

    ACT-179811 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Cadazolid (Standard) is the analytical standard of Cadazolid. This product is intended for research and analytical applications. Cadazolid (ACT-179811) is a new oxazolidinone antibiotic with potent activity against Clostridium difficile.
    Cadazolid (Standard)
  • HY-128357A
    Ibezapolstat hydrochloride

    ACX-362E hydrochloride; GLS-362E hydrochloride

    		 Bacterial DNA/RNA Synthesis Infection
    Ibezapolstat hydrochloride is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat hydrochloride is developed for the research of C. difficile infection(CDI) .
    Ibezapolstat hydrochloride
  • HY-138135
    OP-1118

    Fidaxomicin metabolite OP-1118

    		 NF-κB ERK Apoptosis Bacterial Infection
    OP-1118 (Fidaxomicin metabolite OP-1118) is an orally active dual inhibitor of NF-κB and ERK1/2, with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-κB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis, and its protective effect can be reversed by PMA (HY-18739) .
    OP-1118
  • HY-131476
    NAI-802

    		Bacterial Infection
    NAI-802 is a new lantibiotic. NAI-802 can be produced by Actinoplanes sp. NAI-802 shows a significant activity against Gram-positive anaerobic bacteria, such as Clostridium difficile, C. butyricum, C. perfringens and Peptostreptococcus asaccharolyticus with MIC ranges of 0.25-2 μg/mL .
    NAI-802
  • HY-116880
    DS-2969b

    		Bacterial DNA/RNA Synthesis Infection
    DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC90: 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin (HY-17580), Metronidazole (HY-B0318), and Vancomycin (HY-B0671), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies .
    DS-2969b
  • HY-182464
    DABMA

    		Potassium Channel Infection Others
    DABMA is a TMEM175 channel activator with a human EC50 of 17.9 μM. DABMA directly increases TMEM175 channel current via interaction with intracellular, transmembrane, or endosomal lumen-associated domains, and does not alter TMEM175 mRNA or protein levels. DABMA delays endolysosomal substrate degradation, modulates endolysosomal trafficking, increases acidic organelle accumulation, induces cholesterol accumulation and altered late endosome morphology. DABMA can be used for the research of coronavirus disease, Clostridium difficile infection, Pseudomonas aeruginosa infection, rabies, and influenza virus infection .
    DABMA
  • HY-181819
    Antibacterial agent 327

    		Bacterial Topoisomerase Infection
    Antibacterial agent 327 (Compound 6f) is an Antibacterial agent. Antibacterial agent 327 potently inhibits the supercoiling activity of Staphylococcus aureus DNA gyrase with an IC50 of 0.28 μM. It also inhibits the ATPase activities of DNA gyrase and Topoisomerase IV, as well as the decatenation activity of Topoisomerase IV (IC50: 0.43 μM, 0.73 μM, and 2.31 μM, respectively). Antibacterial agent 327 potently inhibits Clostridioides difficile and methicillin-resistant Staphylococcus aureus (HY-121544), with an MIC of 0.78 μg/mL for both. Antibacterial agent 327 inhibits Escherichia coli with an MIC50 of 0.78 μg/mL .
    Antibacterial agent 327

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: